Secosteroid-quinoline hybrids as new anticancer agents

J Steroid Biochem Mol Biol. 2023 Apr:228:106245. doi: 10.1016/j.jsbmb.2022.106245. Epub 2023 Jan 3.

Abstract

An elegant approach to unknown secosteroid-quinoline hybrids is disclosed. A series of 13,17-secoestra-1,3,5(10)-trien-17-oic acid [N'-(iso)quinolylmethylene]hydrazides was prepared and these novel type of secosteroids was screened for antiproliferative activity against estrogen-responsive human breast cancer cell line MCF-7. Most of the synthesized compounds showed a cytotoxic effect superior to that of reference drug cisplatin; the lead compound exhibits the highest activity with the IC50 value of about 0.8 μM and is 7 times more active than cisplatin. A high selectivity index was observed for the hit 13,17-secoestra-1,3,5(10)-trien-17-oic acid [N'-quinolylmethylene]hydrazides 2a and 2c. Compounds 2a and 2c evaluated in luciferase reporter assays exhibited high antiestrogenic potency which was superior to that of tamoxifen. These hit compounds were characterized by high activity against MCF-7 cells that retained towards multidrug-resistant NCI/ADR-RES cells.

Keywords: Azomethines; Breast cancer; Cytotoxicity; Estrogen receptor α; Hydrazides; Quinolines; Secosteroids.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation
  • Cisplatin / pharmacology
  • Drug Screening Assays, Antitumor
  • Humans
  • Molecular Structure
  • Quinolines* / pharmacology
  • Secosteroids* / pharmacology
  • Structure-Activity Relationship
  • Trientine / pharmacology

Substances

  • Cisplatin
  • Trientine
  • Antineoplastic Agents
  • Quinolines
  • Secosteroids